At the time of writing, Elevation Oncology Inc [ELEV] stock is trading at $0.29, up 4.93%. An important factor to consider is whether the stock is rising or falling in short-term value. The ELEV shares have gain 19.63% over the last week, with a monthly amount drifted -44.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Elevation Oncology Inc [NASDAQ: ELEV] stock has seen the most recent analyst activity on March 24, 2025, when Stephens downgraded its rating to a Equal-Weight and also revised its price target to $1 from $5. Previously, Piper Sandler downgraded its rating to Neutral on March 21, 2025, and kept the price target unchanged to $0.70. On March 21, 2025, downgrade downgraded it’s rating to Market Perform but maintained its price target of $1 on the stock. Citizens JMP downgraded its rating to a Mkt Perform. William Blair initiated its recommendation with a Outperform. Piper Sandler started tracking with a Overweight rating for this stock on May 31, 2024, and assigned it a price target of $10. In a note dated May 14, 2024, Stephens initiated an Overweight rating and provided a target price of $8 on this stock.
For the past year, the stock price of Elevation Oncology Inc fluctuated between $0.22 and $4.92. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Elevation Oncology Inc [NASDAQ: ELEV] shares were valued at $0.29 at the most recent close of the market. An investor can expect a potential return of 3003.45% based on the average ELEV price forecast.
Analyzing the ELEV fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.62 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2755 points at the first support level, and at 0.2573 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3047, and for the 2nd resistance point, it is at 0.3157.
Ratios To Look Out For
It is important to note that Elevation Oncology Inc [NASDAQ:ELEV] has a current ratio of 21.21. On the other hand, the Quick Ratio is 21.21, and the Cash Ratio is 11.07.
